维康药业(300878) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥73,804,856.95, a decrease of 36.13% compared to the same period last year[3] - The net profit attributable to shareholders for Q3 2024 was -¥55,835,041.88, reflecting a significant decline of 911.99% year-over-year[3] - The basic earnings per share for Q3 2024 was ¥0.21, an increase of 532.21% compared to the same period last year[3] - Total operating revenue for Q3 2024 was CNY 370,849,453.15, a decrease of 14.15% from CNY 432,001,715.94 in the same period last year[12] - Net profit attributable to shareholders of the parent company was CNY 44,097,475.42, down 36.48% from CNY 69,350,633.99 in the previous year[14] - Basic and diluted earnings per share decreased to CNY 0.31 from CNY 0.48 year-over-year[14] - The total comprehensive income for the period was CNY 46,205,071.06, compared to CNY 70,873,328.94 in the same period last year[14] Assets and Liabilities - Total assets at the end of Q3 2024 amounted to ¥1,835,044,508.64, down 10.34% from the end of the previous year[3] - The company's total current assets amount to ¥788,459,881.47, down from ¥1,034,759,890.59 at the beginning of the period[11] - The total assets of the company are ¥1,835,044,508.64, a decrease from ¥2,046,636,530.88 at the beginning of the period[11] - Total liabilities decreased to CNY 471,009,219.72 from CNY 639,227,731.24 year-over-year, reflecting a reduction of 26.36%[12] - Non-current liabilities increased to CNY 318,342,360.54, up 53.00% from CNY 207,997,822.74 in the previous year[12] Cash Flow - The net cash flow from operating activities for Q3 2024 was -¥35,228,627.08, a decrease of 230.56% compared to the same period last year[7] - Cash generated from operating activities was CNY 345,497,621.08, compared to CNY 386,343,490.53 in the same period last year[15] - The net cash flow from operating activities was -35,228,627.08, a decrease from 26,982,615.30 in the previous year[16] - The cash flow from investing activities for Q3 2024 was ¥213,599,273.64, a significant improvement compared to -¥112,332,343.13 in the same period last year[7] - Total cash inflow from investment activities was 310,434,591.87, compared to 252,244,395.95 in the same period last year[16] - The net cash flow from investment activities increased significantly to 213,599,273.64, reversing from -112,332,343.13 in the previous year[16] - Cash outflow from financing activities totaled 59,198,303.55, while cash inflow was 181,262,120.00, resulting in a net cash flow of -181,480,682.24[16] - The ending balance of cash and cash equivalents was 326,582,328.27, compared to 161,407,766.90 at the end of the same period last year[16] - The company reported a total cash outflow from operating activities of 401,429,107.25, an increase from 372,607,381.03 in the previous year[16] Expenses - The company experienced a 32.10% increase in selling expenses, totaling ¥163,238,779.57, primarily due to increased marketing costs[6] - The company reported a decrease in research and development expenses by 38.69%, totaling ¥12,180,680.93, due to reduced outsourcing to CRO companies[6] - Total operating costs increased to CNY 414,716,527.66, up 15.36% from CNY 359,422,532.30 year-over-year[13] - Research and development expenses were CNY 12,180,680.93, down 38.67% from CNY 19,866,229.36 year-over-year[13] Shareholder Information - The total number of common shareholders at the end of the reporting period is 11,199, with the top 10 shareholders holding 60.89% of the shares[8] - Liu Zhongliang, the largest shareholder, holds 88,160,400 shares, representing 60.89% of the total shares[8] - The company has a total of 0 shares of preferred stock held by shareholders[10] - The company has not reported any changes in the top 10 shareholders due to margin trading or lending[9] Other Information - The company did not undergo an audit for the third quarter report[17] - The company began implementing new accounting standards starting in 2024[17]